CO2024002712A2 - Azálidos inmunomoduladores - Google Patents
Azálidos inmunomoduladoresInfo
- Publication number
- CO2024002712A2 CO2024002712A2 CONC2024/0002712A CO2024002712A CO2024002712A2 CO 2024002712 A2 CO2024002712 A2 CO 2024002712A2 CO 2024002712 A CO2024002712 A CO 2024002712A CO 2024002712 A2 CO2024002712 A2 CO 2024002712A2
- Authority
- CO
- Colombia
- Prior art keywords
- formula
- immunomodulatory
- disorder
- inflammatory
- animal
- Prior art date
Links
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000026278 immune system disease Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
Abstract
Se definen en la presente compuestos inmunomoduladores de la Fórmula (1), en donde R, R0, R1, R2 y W son como se definen en la presente, estereoisómeros de estos, y sales aceptables desde el punto de vista farmacéutico de estos; y composiciones que comprenden dichos compuestos. La invención también incluye métodos para tratar o prevenir una enfermedad o trastorno inflamatorio y/o inmunológico en un animal al administrar una cantidad terapéuticamente eficaz de un compuesto de la Fórmula (1), un estereoisómero de este o una sal aceptable desde el punto de vista farmacéutico de este; o el uso de dicho compuesto de la Fórmula (1) para preparar un medicamento para tratar o prevenir una enfermedad o trastorno inflamatorio y/o inmunológico en un animal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163241126P | 2021-09-07 | 2021-09-07 | |
| PCT/US2022/042421 WO2023038852A1 (en) | 2021-09-07 | 2022-09-02 | Immunomodulating azalides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024002712A2 true CO2024002712A2 (es) | 2024-03-27 |
Family
ID=83457385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0002712A CO2024002712A2 (es) | 2021-09-07 | 2024-03-04 | Azálidos inmunomoduladores |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230129040A1 (es) |
| KR (1) | KR20240056746A (es) |
| AU (1) | AU2022343476A1 (es) |
| CA (1) | CA3231535A1 (es) |
| CO (1) | CO2024002712A2 (es) |
| WO (1) | WO2023038852A1 (es) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2064634C (en) * | 1991-04-04 | 1998-08-04 | James V. Heck | 9-deoxo-8a-aza-8a-homoerythromycin a derivatives modified at the 4"- and8a-positions |
| PT1250343E (pt) | 2000-01-27 | 2003-11-28 | Pfizer Prod Inc | Composicoes de antibioticos de azalida |
| BR0110382A (pt) * | 2000-04-27 | 2003-06-24 | Pfizer Prod Inc | Utilização de composições antibióticas azalida para o tratamento ou prevenção de uma infecção causada por bactérias ou protozoários em mamìferos |
| ITMI20040124A1 (it) * | 2004-01-29 | 2004-04-29 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria |
| WO2009023196A1 (en) * | 2007-08-10 | 2009-02-19 | Y's Therapeutics Co, Ltd. | Modulation of immune responses by administration of roxithromycin or its derivative |
| AU2014252462A1 (en) | 2013-04-10 | 2015-10-01 | Probiotic Pharmaceuticals Aps | Azithromycin antimicrobial derivatives with non-antibiotic pharmaceutical effect |
| GB201520419D0 (en) * | 2015-11-19 | 2016-01-06 | Epi Endo Pharmaceuticals Ehf | Compounds |
| GB201608236D0 (en) * | 2016-05-11 | 2016-06-22 | Fidelta D O O | Seco macrolide compounds |
| WO2021183754A1 (en) | 2020-03-12 | 2021-09-16 | Zoetis Services Llc | Immunomodulating trifluoromethyl-aminal azalides |
-
2022
- 2022-09-02 WO PCT/US2022/042421 patent/WO2023038852A1/en active Application Filing
- 2022-09-02 AU AU2022343476A patent/AU2022343476A1/en active Pending
- 2022-09-02 CA CA3231535A patent/CA3231535A1/en active Pending
- 2022-09-02 KR KR1020247011525A patent/KR20240056746A/ko active Search and Examination
- 2022-09-06 US US17/929,777 patent/US20230129040A1/en active Pending
-
2024
- 2024-03-04 CO CONC2024/0002712A patent/CO2024002712A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023038852A1 (en) | 2023-03-16 |
| KR20240056746A (ko) | 2024-04-30 |
| AU2022343476A1 (en) | 2024-03-21 |
| CA3231535A1 (en) | 2023-03-16 |
| US20230129040A1 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| DOP2020000058A (es) | Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas | |
| PE20220762A1 (es) | Derivados de acido itaconico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunitaria indeseable | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| AR053162A1 (es) | Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma. | |
| CY1114163T1 (el) | Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση | |
| GT200600160A (es) | Tratamiento del dolor | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| CO2023001668A2 (es) | Derivados de 1h-benzo[d]imidazol como inhibidores de tlr9 para el tratamiento de fibrosis | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| AR062393A1 (es) | Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor | |
| NI202100012A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| ECSP19084722A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| BR112012020377A8 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
| CO2024002712A2 (es) | Azálidos inmunomoduladores | |
| CO2023004420A2 (es) | Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300 | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
| ECSP21093897A (es) | Compuestos y métodos de uso de los mismos como agentes antibacterianos | |
| CL2021003303A1 (es) | Tratamiento para sinucleinopatías. | |
| UY39466A (es) | Compuestos y composiciones para el tratamiento de la criptosporidiosis | |
| AR126835A1 (es) | Análogos deuterados y derivados de 4-bromo-2,5-dimetoxifenetilamina y usos de estos | |
| AR108792A1 (es) | Composiciones que comprenden timolol | |
| BR112023016459A2 (pt) | Métodos terapêuticos |